Dodge & Cox Alnylam Pharmaceuticals, Inc. Call Options Transaction History
Dodge & Cox
- $166 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALNY
# of Institutions
742Shares Held
115MCall Options Held
584KPut Options Held
672K-
Capital World Investors Los Angeles, CA16.8MShares$7.59 Billion0.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$6.01 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.31 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.19MShares$3.25 Billion0.49% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.28MShares$1.93 Billion0.88% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.6B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...